Sectoral Asset Management Has Boosted Its Aerie Pharmaceuticals (AERI) Position; Last Week Ballard Power Systems Inc. (USA) (BLDP) Coverage

November 15, 2017 - By Louis Casey

Sectoral Asset Management Inc increased Aerie Pharmaceuticals (AERI) stake by 3.4% reported in 2017Q2 SEC filing. Sectoral Asset Management Inc acquired 13,251 shares as Aerie Pharmaceuticals (AERI)’s stock declined 8.47%. The Sectoral Asset Management Inc holds 402,674 shares with $21.16 million value, up from 389,423 last quarter. Aerie Pharmaceuticals now has $2.13 billion valuation. The stock declined 4.13% or $2.5 reaching $58.1 on the news. About 33,817 shares traded. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 180.20% since November 15, 2016 and is uptrending. It has outperformed by 163.50% the S&P500.

Among 4 analysts covering Ballard Power Systems (NASDAQ:BLDP), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Ballard Power Systems had 12 analyst reports since August 20, 2015 according to SRatingsIntel. As per Monday, August 14, the company rating was maintained by Cowen & Co. The stock of Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) earned “Buy” rating by FBR Capital on Thursday, June 22. The rating was reinitiated by H.C. Wainwright on Thursday, August 20 with “Buy”. The rating was maintained by Roth Capital on Wednesday, November 1 with “Hold”. The company was initiated on Thursday, August 20 by Rodman & Renshaw. On Friday, September 15 the stock rating was maintained by Cowen & Co with “Hold”. H.C. Wainwright maintained the shares of BLDP in report on Friday, August 4 with “Buy” rating. Cowen & Co maintained Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) on Thursday, July 13 with “Hold” rating. The firm has “Hold” rating by Roth Capital given on Monday, July 31. On Monday, October 16 the stock rating was maintained by Cowen & Co with “Hold”. See Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) latest ratings:

14/11/2017 Broker: FBR Capital Rating: Buy New Target: $6.0
01/11/2017 Broker: Roth Capital Rating: Hold New Target: $5.0 Maintain
16/10/2017 Broker: Cowen & Co Rating: Hold New Target: $4.5 Maintain
18/09/2017 Broker: Inc. – Common Shares Rating: Fbr Capital New Target: $3.5 6
15/09/2017 Broker: Cowen & Co Rating: Hold New Target: $4.5 Maintain
14/08/2017 Broker: Cowen & Co Rating: Hold New Target: $3.0000 Maintain
04/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.0000 Maintain
31/07/2017 Broker: Roth Capital Rating: Hold New Target: $3.0000 Maintain
13/07/2017 Broker: Cowen & Co Rating: Hold New Target: $3.0000 Maintain
22/06/2017 Broker: FBR Capital Rating: Buy New Target: $3.5000 Maintain

About 1.50M shares traded. Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) has risen 104.41% since November 15, 2016 and is uptrending. It has outperformed by 87.71% the S&P500.

Ballard Power Systems Inc. is engaged in the design, development, manufacture, sale and service of proton exchange membrane fuel cell products for a range of applications, focusing on the power product markets of heavy-duty motive (consisting of bus and tram applications), portable power, material handling and backup power, as well as the delivery of technology solutions, including engineering services, technology transfer and the license and sale of its intellectual property portfolio and fundamental knowledge for a range of fuel cell applications. The company has market cap of $820.74 million. As of December 31, 2016, the Company provided products in four product classes, such as Fuel cell stacks, Fuel cell modules, Fuel cell systems and Power management systems. It currently has negative earnings.

Investors sentiment increased to 1.17 in Q2 2017. Its up 0.21, from 0.96 in 2017Q1. It increased, as 21 investors sold AERI shares while 48 reduced holdings. 33 funds opened positions while 48 raised stakes. 31.61 million shares or 3.55% more from 30.53 million shares in 2017Q1 were reported. Foresite Capital Mgmt Ii Limited Liability Company reported 1.67 million shares or 40.27% of all its holdings. Barclays Plc stated it has 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Citadel Advsrs Lc reported 0% stake. National Bank Of Nova Scotia owns 0.01% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 22,300 shares. Credit Suisse Ag stated it has 56,111 shares. Moreover, National Bank & Trust Of Ny Mellon Corporation has 0.01% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Fmr Lc accumulated 305,034 shares or 0% of the stock. Tocqueville Asset Mngmt Ltd Partnership invested 0.08% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Ameritas Invest Partners owns 0.01% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 2,665 shares. Benchmark Capital Advisors has invested 0.56% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Aperio Group Ltd Limited Liability Company reported 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Moreover, United Capital Financial Advisers Llc has 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Deutsche Bancshares Ag has 419,878 shares for 0.02% of their portfolio. 5,521 are owned by First Mercantile Company. Grp One Trading Limited Partnership has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Among 14 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 41 analyst reports since August 7, 2015 according to SRatingsIntel. As per Thursday, July 27, the company rating was maintained by Stifel Nicolaus. As per Monday, October 16, the company rating was maintained by Canaccord Genuity. The firm earned “Outperform” rating on Friday, October 28 by RBC Capital Markets. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, October 6. As per Thursday, September 15, the company rating was maintained by Cantor Fitzgerald. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) has “Buy” rating given on Thursday, September 15 by Stifel Nicolaus. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright on Wednesday, August 2. The stock has “Buy” rating by Cowen & Co on Thursday, November 9. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, July 20. Cowen & Co maintained the stock with “Buy” rating in Thursday, October 5 report.

Sectoral Asset Management Inc decreased Tg Therapeutics (NASDAQ:TGTX) stake by 56,234 shares to 81,266 valued at $817,000 in 2017Q2. It also reduced Teladoc Inc stake by 515,480 shares and now owns 543,073 shares. Ptc Therapeutics I (NASDAQ:PTCT) was reduced too.

Since May 26, 2017, it had 0 insider buys, and 1 sale for $1.12 million activity. Foresite Capital Management II – LLC sold 20,000 shares worth $1.12M.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com